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We thank Dr Gurewich [1] for his critical evaluation of the
impact of our recently published article on factor XIII
(FXIII) [2]. This article reports that mechanical com-
paction or platelet-mediated retraction of plasma clots is
essential to fully reveal the antifibrinolytic effect of FXIII
on tissue-type plasminogen activator (t-PA)-induced
plasma clot lysis. Gurewich argues that we cannot assume
that these results are applicable to endogenous fibrinolysis
in vivo, because endogenous fibrinolysis depends not only
on t-PA, but also on urokinase-type plasminogen activator
(u-PA).
We fully agree that the role of u-PA in fibrin degrada-
tion is frequently underestimated or even neglected in the
literature on fibrinolysis, as discussed in our review on
the molecular transport of fibrinolytic components during
fibrin clot lysis [3]. The relative contributions of t-PA and
u-PA to fibrinolysis, however, may depend on the design
of the in vitro test system or on the particular thrombosis
model applied in experimental animals [4,5]. In addition,
it is quite possible that the relative contributions of t-PA
and u-PA to fibrinolysis in vivo vary, depending on the
mechanism and site of thrombus formation, and the
speed of thrombus resolution.
Although we agree that the role of u-PA in fibrin
degradation is frequently underestimated, we probably
estimate the relative contribution of t-PA to endogenous
fibrinolysis to be greater than Gurewich does. For
instance, Gurewich et al. [6] observed only a limited role
of t-PA in the spontaneous lysis of platelet-rich plasma
clots. The source of t-PA activity in their experiments was
pooled normal plasma, which contains hardly any free t-
PA, owing to the rapid formation of a complex with plas-
minogen activator inhibitor-1 [7]. In contrast, the t-PA
activity in the plasma compartment of circulating blood is
much higher, because a substantial proportion of t-PA in
blood is in its free form [8].
In addition, it is still a matter of dispute whether
endogenous fibrinolysis in a blood vessel depends on sys-
temic levels of plasminogen activators, on local release of
t-PA by injured endothelial cells, or on both [9]. If local
release of t-PA is important, then the contribution of
t-PA to endogenous fibrinolysis is more substantial than
studies with isolated blood or plasma suggest.
Finally, the antifibrinolytic effect of FXIII is
explained by the cross-linking of a2-antiplasmin to fib-
rin, which prevents the plasmin inhibitor from being
expelled from the clot during compaction or retraction
[2]. This mechanism primarily involves a2-antiplasmin,
which is able to inhibit plasmin that is generated either
by t-PA or by u-PA [10]. It is therefore likely that the
new mechanism is also applicable to endogenous fibri-
nolysis, even if u-PA is the most prominent plasminogen
activator.
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